SHAREHOLDERS OCTOPLUS APPOINT TWO NEW SUPERVISORY BOARD MEMBERS
This is a press release by OctoPlus N.V. ("OctoPlus"or the "Company") pursuant
to the provisions of Article 5:25i of the Dutch Act on the Financial Supervision
(Wet op het financieel toezicht) and Article 4, paragraph 3 of the Dutch Public
Takeover Decree (Besluit openbare biedingen Wft), in connection with the
recommended public offer (the "Offer") by Reddy Netherlands B.V. (the
"Offeror"), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. ("Dr.
Reddy's") for all the issued and outstanding ordinary shares (the "Shares") in
the capital of OctoPlus.
SHAREHOLDERS OCTOPLUS APPOINT TWO NEW SUPERVISORY BOARD MEMBERS
OctoPlus N.V. ("OctoPlus")(Euronext: OCTO), announces today that its
Extraordinary General Meeting of Shareholders has appointed Mr. Prasad and Mr.
Ananthanarayanan to the Supervisory Board. The appointment is subject to the
condition precedent that the Offer is declared unconditional and is settled.
The new members of the Supervisory Board have been appointed for a period of
four years and join current member Staf Van Reet to form a Supervisory Board of
three members. Mr. Prasad has been appointed as chairman of the Supervisory
Board.
The shareholders also approved the other agenda item of today's meeting. Minutes
of the meeting will be available within three months on OctoPlus' website
www.octoplus.nl.
For further information, please contact:
Investor relations: telephone number +31 (71) 524 1071, or send an e-mail to
Investor Relations at IR@octoplus.nl.
About OctoPlus
OctoPlus is a leading European provider of advanced drug formulation and
clinical scale manufacturing services to the pharmaceutical and biotechnology
industries, with a focus on difficult to formulate active pharmaceutical
ingredients. OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the
symbol OCTO. For more information about OctoPlus, please visit our website
www.octoplus.nl.
In addition, OctoPlus is a specialty pharmaceutical company focused on the
development and manufacture of improved injectable pharmaceuticals based on our
proprietary drug delivery technologies that exhibit fewer side effects, improved
patient convenience and a better efficacy/safety balance than existing
therapies. OctoPlus also focuses on the development of long-acting, controlled
release versions of known protein therapeutics, peptides and small molecules,
including specialty generics.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF:
http://hugin.info/137076/R/1670571/542898.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1670571]
